PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	10/742,346	
Confirmation No.	6421	
Filing Date	December 19, 2003	
First Named Inventor	Robert Falotico	
Group Art Unit	1615	
Examiner Name	Caralynne Helm	
Attorney Docket Number	CRD5062USNP	

U.S. PATENT DOCUMENTS					
Cite	U.S. Patent Document			0.4 (0.4)	
	Kind Code <sup>2</sup> Number (if known)		Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages o relevant figures appear
	6,153,252	Α	Hossainy, et al.	11-28-2000	
	1	Cite No. <sup>1</sup> Number	Cite Kind Code <sup>2</sup> No. <sup>1</sup> Number (if known)	Cite No.1 Number (if known)  Name of Patentee or Applicant of Cited Document	Cite No.1 Number (if known)  Name of Patentee or Applicant of Cited Document  Name of Patentee or Applicant of Cited Document  mm-dd-yyyy

## FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite $\mathsf{T}^6$ mm-dd-yyyy Applicant of Cited Document Initials figures appear Office<sup>3</sup> Number⁴ KindCode5 No.1

Examiner	10 1 11 1	Date	05/06/2010
Signature	/Caralynne Helm/	Considered	05/06/2010

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a conceitor of information diffess it displays a valid of the control number:		
Application Number	10/742,346	
Confirmation No.	6421	
Filing Date	December 19, 2003	
First Named Inventor	Robert Falotico	
Group Art Unit	1615	
Examiner Name	Caralynne Helm	
Attorney Docket Number	CRD5062USNP	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		AJROLDI, G, et al. "Fluoroelastomers-Dependence of Relaxation Phenomena on Composition", Polymer, Volume 30 (1989) pp. 2180-2187	
		CAMPBELL, G., et al. "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture", Table of Contents, Chapter 4, Volume 1, p. 39 (1985)	
		CLOWES and CLOWES, "Kinetics of Cellular Proliferation After Arterial Injury", Laboratory Investigation, Vol. 52, No. 6 (1985) pp. 611-616	
		DEROANNE, C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling", Oncogene, Volume 21 (2002) pp. 427-436	
		LANG, R., et al. "Effects of Okadaic Acid and ATPγS on Cell Length and Ca <sup>2+</sup> - Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", British Journal of Pharmacology, Vol. 104 (1991) pp. 331-336	
		MINTZ, G., et al. "Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization", JACC, Vol. 27, No. 7 (1996) pp. 1678-1687	
		MINTZ, G., et al. "Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study", Circulation, Volume 94(1) (1996) pp. 35-43	
		SERRUYS, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Clinical Investigations and Reports, Volume 93(3) (1996) pp. 412-422	
		WOO, S., et al. "Structurally simple Trichostatin a-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors", J. Medical Chemistry, Volume 45 (2002) pp. 2877-2885	

Examiner Signature /Caralynne Helm/	Date Considered	05/06/2010
-------------------------------------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.